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ABSTRACT
Introduction Major depression is a highly prevalent 
pathology that is currently the second most common 
cause of disease- induced disability in our society. The 
onset and continuation of depression may be related to a 
wide variety of biological and psychosocial factors, many 
of which are linked to different lifestyle aspects. Therefore, 
health systems must design and implement health 
promotion and lifestyle modification programmes (LMPs), 
taking into account personal factors and facilitators. The 
main objective of this protocol is to analyse the clinical 
effectiveness, cost- effectiveness and cost utility of an 
LMP and an LMP with information and communication 
technologies (ICTs) as adjunctive treatment for depression 
in primary care patients. The secondary objectives are 
to analyse the clinical effectiveness in the subgroup 
that presents comorbidity and to analyse the correlation 
between personal factors on health behaviour and lifestyle 
patterns.
Methods and analysis A randomised, multicenter 
pragmatic clinical trial with three parallel groups 
consisting of primary healthcare patients suffering from 
subclinical, mild or moderate depression. The following 
interventions will be used: (1) Usual antidepressant 
treatment with psychological advice and/or psychotropic 
drugs prescribed by the general practitioner (treatment as 
usual (TAU)). (2) TAU+LMP. A programme to be imparted in 
six weekly 90- minute group sessions, intended to improve 
the following aspects: behavioural activation+daily 
physical activity+adherence to the Mediterranean diet 
pattern+sleep hygiene+careful exposure to sunlight. 
(3) TAU+LMP+ICTs: healthy lifestyle recommendations 
(TAU+LMP)+monitoring using ICTs (a wearable 
smartwatch). The primary outcome will be the depressive 
symptomatology and the secondary outcomes will be 
the quality of life, the use of health and social resources, 
personal factors on health behaviour, social support, 
lifestyle patterns and chronic comorbid pathology. Data 
will be collected before and after the intervention, with 
6- month and 12- month follow- ups.
Ethics and dissemination This study has been approved 
by the Clinical Research Ethics Committee of Aragón 
(approval number: C.P.-C.I. PI18/286) and the Research 
Ethics Committee of the Balearic Islands (IB3950/19 
PI). Data distribution will be anonymous. Results will be 
disseminated via conferences and papers published in 
peer- reviewed, open- access journals.
Trial registration number  ClinicalTrials. gov Registry 
(NCT03951350).
INTRODUCTION
Depression is considered to be the principle 
cause of disability worldwide, and it contrib-
utes to the overall global burden of morbidity 
and mortality. By 2030, it is expected to 
be the main contributor to the burden of 
morbidity.1–3 Approximately 25%–35% of all 
primary care patients suffer from psychiatric 
disorders, and over 80% of these patients 
suffer from depression or anxiety disor-
ders.4 5 In Spanish primary healthcare centres 
Strengths and limitations of this study
 ► The intervention has the potential to be highly scal-
able and sustainable for the Spanish National Health 
Service.
 ► Increased motivation, on introducing self- registers 
for everyone and a group that will be monitored us-
ing wearable smartwatches.
 ► Most healthcare professionals can implement the 
intervention groups.
 ► Some individuals may refuse to participate in group 
intervention or may withdraw from the study during 
the 12- month trial period.
 ► Difficulty of entire group’s attendance to a session 
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(PHCs), the prevalence of depression ranges from 9.6% 
to 20.2%.6 7 Furthermore, depression generates great 
disability and high economic and social costs.8
The prevalence of depression in Spain is 13% over 
one’s lifetime and 4% per year.9 Indeed, comorbidity 
with other chronic conditions is high (64.9%–71.0%) 
(diabetes, hypertension, cardiovascular diseases and 
cancer, among others)10–12 as well as comorbidity with 
other psychiatric diseases such as anxiety disorders is also 
high (40%–66%).13
Despite the negative impact of depression on people’s 
lives and the existence of numerous treatment interven-
tions,14 these interventions are often not appropriately 
used in PHC services,6 mainly due to physician time or 
resource limitations.7 Thus, pharmacological15 treatment 
is usually recommended, even though research has shown 
that in subclinical, mild or moderate depression, non- 
pharmacological interventions are recommended.15 16
Since options and outcomes for the care of individuals 
suffering from depression and their access to treatment 
remains limited,17 it is important to promote cost- 
effective treatment options. The onset and continuation 
of depression has been linked to numerous biological 
and psychosocial factors, many of which are related to 
distinct lifestyle aspects.18–21 Therefore, many of the strat-
egies promoting a healthier lifestyle could have antide-
pressant utility.20 22–24 In addition to multimodal studies, 
others have focused on one of the following aspects of 
lifestyle modification: daily physical activity,25 adherence 
to the Mediterranean diet,26 27 sleep hygiene practices28 29 
and careful exposure to sunlight.30 31
The present study will be framed around the theory 
of salutogenesis,32 which establishes that an individual’s 
ability to modify our lifestyle is influenced by psychoso-
cial generalised resistance resources, which consist of 
personal, interpersonal or contextual resources (money, 
knowledge, experience, self- esteem, healthy habits, 
commitment, social support, cultural capital, intelligence, 
traditions and vision of life) and the sense of coherence 
(way of making sense of the world, which is a major factor 
in determining how well an individual manages stress and 
stays healthy).
Moreover, previous studies show that the use of facilita-
tors is quite important (simplicity of guidelines, tailoring 
through motivational interviewing, prolonged and 
intense monitoring throughout the different stages of 
the disorder and the provision of adequate feedback and 
social support)23 to facilitate adherence to lifestyle modi-
fication programmes (LMPs). For example, enhanced 
motivation can be achieved through the use of informa-
tion and communication technologies (ICTs) and with 
the social support resulting from intervention group 
participation.33 Personal factors and facilitators must be 
taken into account in lifestyle modification interventions, 
since they may determine the success of health promo-
tion programmes.
The main objective of this protocol is to analyse the 
clinical effectiveness, cost- effectiveness and cost utility of 
an LMP and an LMP with ICTs as adjunctive treatment 
for depression in primary care patients. The secondary 
objectives are to analyse the clinical effectiveness in the 
subgroup that presents comorbidity and to analyse the 




Multicenter pragmatic randomised controlled trial in 
three parallel groups.
Setting and study sample
We will recruit patients having subclinical, mild or 
moderate depression (scoring ≥10 and ≤30 points on the 
Beck II Self- Applied Depression Inventory (BDI- II))34 
from PHCs of two Spanish areas (Zaragoza and Mallorca). 
Inclusion criteria: individuals over the age of 18, both 
sexes, having a duration of depression symptoms of at least 
2 months, who understand written and spoken Spanish 
and who have provided their informed consent (online 
supplemental file 1). Exclusion criteria will be: suffering 
from another disease that affects the brain (organic brain 
pathology or having suffered a traumatic brain injury of 
any severity, dementia); having another psychiatric diag-
nosis or serious psychiatric illness (substance dependence 
or abuse, a history of schizophrenia or other psychotic 
disorders, eating disorders) with the exception of anxious 
pathology or personality disorders (collected through a 
medical history and from the Mini- International Neuro-
psychiatric Interview (MINI))35; presence of a serious or 
uncontrolled medical, infectious or degenerative illness 
that may interfere with the affective symptoms; the pres-
ence of delirium or hallucinations, risk of suicide, preg-
nancy or lactation; patients who have participated in 
another clinical trial over the past 6 months, who are 
currently in psychotherapy or those who have been prac-
ticing mindfulness, yoga, meditation or similar practices 
over the past 6 months, engaging in formal practice at 
least once a week and the presence of any medical, 
psychological or social problem that could seriously inter-
fere with the patient’s participation in the study.
Sample size
Scientific evidence suggests that a 17% reduction in the 
BDI- II34 is considered clinically relevant.36 In a previous 
study conducted by our team with psychiatric outpatients, 
we found that the average BDI score at the beginning 
of the study was 24.5 points (SD 9.8),22 so we consider 
that a reduction of at least 4.8 points would have clinical 
significance and would benefit the patient. Accepting an 
α risk of 0.05 and a β risk of 0.20 in a bilateral contrast, 
44 subjects will be required for each group. With an 
estimated withdrawal rate of 20%, the sample size will 
require approximately 53 patients in each group. The 
total sample required is 159 subjects. A formula based 
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online supplemental file 2). It is estimated that approxi-
mately 50% of these patients will present some physical or 
mental comorbidity.12
Recruitment
General practitioners (GPs) from the PHCs of Zara-
goza and Mallorca will be invited to refer patients who 
are suspected of suffering from depression. Most repre-
sentative PHCs in the area will be invited, based on size, 
urban or rural area, and PHCs with a different sociode-
mographic profile will be selected. GPs will explain the 
characteristics of the study to their patients and if they 
agree to participate, they will be asked to provide a phone 
number to be contacted by a trained research assistant 
(RA) during the next week. The RA will call patients and 
establish an appointment in their PHC, in which he will 
explain them the study, provide them the patient infor-
mation sheet and get the informed consent signed. To 
ensure that they fulfil the inclusion criteria, the RA will 
administrate the BDI- II34 and the MINI.35 If participants 
meet the criteria, the RA will administer the baseline 
questionnaires at the same appointment. Recruitment 
and baseline assessments will be carried out until the final 
sample size has been achieved.
Randomisation, allocation and masking of study groups
Once baseline data are collected, the participants will be 
randomised. An independent statistician will perform the 
individual randomisation using a computer- generated 
random number sequence. The randomisation will be 
carried out using a list of patients from Zaragoza and 
Mallorca (figure 1). Given the nature of the interven-
tions, participants will not be blinded to their allocation. 
An RA will call them to explain their assigned interven-
tion and where they should go and when. The RA will 
request that participants not to inform other researchers 
of their allocation.
Data collection and monitoring
One RA will collect the data and another will perform 
entry and coding of the identified data. All RA managing 
the data will be blinded to participant allocation, as well 
as the RA conducting the outcome assessments and 
data analysis. All information collected will be treated in 
accordance with the provisions of current legislation on 
personal data protection.
The study will not have a formal data monitoring 
committee since adverse intervention events have not 
been reported. Any serious unexpected adverse events 
or outcomes will be discussed by the trial management 
committee (identical to the authors of this protocol). 
There are no plans to discontinue or modify interven-
tions, or to improve adherence or promote participant 
retention. The trial management committee will monitor 
recruitment, treatment and attrition rates and any 
concerns related to the study. Reasons for dropping out 
will be also registered. Concomitant care is permitted and 
registered as long as it is not one of the exclusion criteria. 
Group- specific processes will be taken into account and 
will be evaluated and informed, in accordance with 
recommendations of the ‘mechanisms of action in group- 
based interventions’ (MAGI) framework.38
Intervention development and evaluation
Patients allocated in the first arm (control group) will 
follow the usual treatment provided by their GP (treat-
ment as usual (TAU)).
Patients allocated in the second arm (first intervention 
group) will follow the TAU and the LMP. This programme 
will consist of six weekly group sessions (lasting 90 min 
each) led by an experienced psychologist and comple-
mented by PowerPoint presentations.
Patients allocated in the third arm (second intervention 
group) will follow TAU and LMP and will be monitored 
using a wearable smart wristwatch that will track their 
daily sleep patterns and physical activity (LMP+ICTs).
The group sessions will consist of the following content:
1. Presentation of the project and psychoeducation on 
depression: presentation of the project and a review 
of the study objectives. Definition, symptoms, causes, 
consequences of depression and, also, how lifestyles 
and social environment changes influence the symp-
tomatology of depression.
2. Behaviour activation: a psychologist will provide infor-
mation on the importance of establishing, maintaining 
Figure 1 Flowchart of the study: randomisation, sampling 
and monitoring of patients. GP, general practitioner; ICTs, 
information and communication technologies; ITT, intention 
to treat; LMP, lifestyle modification programme; MI, multiple 
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and monitoring activities. For the LMP+ICTs group, 
they will also learn how to use the smart wristwatch, 
ensuring all participants are able to use it.
3. Sleep hygiene habits and careful exposure to sunlight: 
recommendations on healthy sleep habits, factors in-
fluencing sleep quality and possible solutions. The 
benefits of careful exposure to sunlight and recom-
mendations of when to do so and for how long. Re-
sponding to questions regarding the previous session.
4. Physical activity: the benefits of engaging in regular 
physical activity. Personalised recommendations about 
what physical exercise may be practiced, how and 
when to do so. Responding to questions regarding the 
previous session.
5. Adherence to the Mediterranean diet: explanations 
about the Mediterranean diet, food groups and their 
characteristics, as well as the most beneficial foods for 
physical and mental health, how to cook it and food- 
related habits. Responding to questions regarding the 
previous session.
6. Summary of previous sessions with practical final sug-
gestions: personalised experiences and doubts of the 
participants throughout the course. Recommendations 
for daily healthy lifestyle practices for the future and 
farewell.
At the end of each session, the participants will receive 
a paper with self- registration tables (online supplemental 
file 3). They will complete the tables with the information 
on their daily routines regarding the modification of life-
styles on which they have been instructed. They will be 
asked about when they wake up and when they go to bed, 
the duration of their sleep, the time spent exposed to 
sunlight, the diet pattern, the physical activity and sports 
practiced, the social support and the subjective percep-
tion of satisfaction after these activities. A qualitative 
study associated with this study will be included to analyse 
the participants' difficulties in following the intervention.
Outcomes and measures
We will collect patient data using the questionnaires 
administered in baseline, immediately after the interven-
tion (in a period of 2–7 days after the last intervention 
session) and at 6- month and 12- month follow- up after the 
last intervention session (with a margin of ±2 weeks) (see 
table 1). A blinded RA will call each patient of the three 
arms and set up an appointment in their PHC for ques-
tionnaire administration. Study outcomes and measures 
are summarised in table 1.
Sociodemographic data
We will collect information on gender, age, marital status, 
education, occupation and economical level. These data 
will be collected through an ad hoc questionnaire.
Table 1 Study variables
Instrument Assessment area Measures
BDI- II34 39 Severity of depression Baseline and follow- up sessions*
MINI35 Psychiatric diagnosis Baseline
Gender, age, marital status, education, occupation, 
economical level
Sociodemographic Baseline and follow- up sessions*
Glucose concentration (mg/dL), glycated haemoglobin 
(%), creatinine, arterial pressure (mm Hg) and cholesterol 
(mg/dL)
Comorbidity with chronic diseases Baseline and 6- month and 
12- month follow- up
EQ- 5D40 42 Health- related quality of life Baseline and follow- up sessions*
MOS- SS46 47 Social support Baseline and follow- up sessions*
CSRI48 49 Health and social services use Baseline and follow- up sessions*
IPAQ- SF50 51 Physical activity Baseline and follow- up sessions*
MEDAS53 54 Adherence to the Mediterranean diet Baseline and follow- up sessions*
PSQI55 56 Quality and patterns of sleep Baseline and follow- up sessions*
Self- Efficacy Scale57 62 Self- efficacy Baseline and follow- up sessions*
PAM58 63 Patient activation in their own health Baseline and follow- up sessions*
SOC-1359 64 Sense of coherence Baseline and follow- up sessions*
HLS- EUQ1660 65 Health literacy Baseline and follow- up sessions*
IPS61 66 Procrastination Baseline and follow- up sessions*
*Follow- up sessions: post intervention (in a period of 2–7 days after the last session of the intervention) and 6- month and 12- month 
follow- up (6 and 12 months after the last session of the intervention (±2 weeks)).
BDI- II, Beck II Self- Applied Depression Inventory; CSRI, Client Service Receipt Inventory; EQ- 5D, European Quality of Life-5 Dimensions 
Questionnaire; HLS- EUQ16, Health Literacy Europe Questionnaire; IPAQ- SF, International Physical Activity Questionnaire- Short Form; 
IPS, Irrational Procrastination Scale; MEDAS, 14- item Mediterranean Diet Adherence Screener; MINI, Mini- International Neuropsychiatric 
Interview; MOS- SS, Medical Outcomes Study Social Support Survey; PAM, Patient Activation Measure Questionnaire; PSQI, Pittsburgh 
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The primary outcome will be measured using the BDI- II.34 
This is a self- report inventory for measuring the severity 
of depression, consisting of 21 multiple- choice questions 
with each answer being scored on a scale ranging from 0 
to 3. It was translated and validated into Spanish with a 
reliability of 0.89.39 The standardised cutoffs are: 0–13: 
minimal depression; 14–19: mild depression; 20–28: 
moderate depression and 29–63: severe depression.
Secondary outcomes
Health-related quality of life
Health- related quality of life will be measured using the 
European Quality of Life-5 Dimensions Questionnaire 
(EQ- 5D).40 41 EQ- 5D scores will be used to calculate 
the quality- adjusted life year (QALY) during the moni-
toring period by adjusting the length of time affected 
by the health result by the utility value. It contains five 
health dimensions (mobility, self- care, usual activities, 
pain/discomfort and anxiety/depression) and each of 
these has three levels (no problems, slight problems or 
moderate and severe problems). The EQ records the 
patient’s self- rated health on a vertical Visual Analogue 
Scale (VAS) of 20 cm, where the endpoints are labelled 
‘The best health you can imagine’ and ‘The worst health 
you can imagine’. The VAS can be used as a quantitative 
measure of health outcome that reflect the patient’s own 
judgement. Patients mark the point on the vertical line 
that best reflects their assessment of their current global 
health status.42 Cronbach’s alpha coefficient has been 
calculated in research with disease- specific populations. 
We highlight the study of Seoane et al43 in which the 
overall alpha value was 0.788. Being the only study with a 
general population, it provides an overall mean estimate 
of the minimum important difference for the EQ- 5D, 
which is 0.074.44
Comorbidity with chronic diseases
Comorbidity with chronic diseases will be determined 
according to the International Classification of Diseases, 
Tenth Revision45: diabetes (glucose concentration 
(mg/dL), glycated haemoglobin (%), creatinine, arte-
rial hypertension and diseases of lipid metabolism. In 
patients with chronic heart disease, coagulation variables 
will be added. They will be collected from the last blood 
test or control measurements of the clinical history, taken 
by their GP or nurse (assuming they were taken over the 
past 3 months). Otherwise, their GP will be asked for a 
blood control test. It is estimated that approximately 50% 
of these patients will present some comorbidity.12 Anthro-
pometric measures will also be collected (weight, size and 
perimeter of the waist).
Social support
It will be measured by the Medical Outcomes Study Social 
Support Survey (MOS- SS).46 It is a self- report instrument 
consisting of four subscales (emotional/informational, 
tangible, affectionate and positive social interaction) and 
an overall functional social support index. It has a good 
reliability (Cronbach’s alpha ≥0.91) and is quite stable 
over time. It has 19 items, a 5- point Likert Scale. Higher 
scores indicate more support. We will use the Spanish vali-
dated version.47
Use of health and social services
It will be measured using the Client Service Receipt Inven-
tory.48 These data may be used for a wide range of appli-
cations, including estimates of the costs of service receipt. 
To collect information on the entire range of services 
and supports used by study participants. It retrospectively 
collects data on the use of services over the past 6 months 
(eg, rates of use of individual services, mean intensity of 
service use, rates of accommodation use over time). We 
will use the validated Spanish version.49
Assessment of lifestyle
Physical activity
Physical activity will be measured using the International 
Physical Activity Questionnaire- Short Form (IPAQ- SF).50 
It assesses the levels of habitual physical activity over the 
last 7 days. It has seven items and records the activity 
of four intensity levels: vigorous- intensity activity and 
moderate- intensity activity (walking and sitting). We will 
use the validated Spanish version.51 IPAQ- SF has accept-
able validity for the measurement of total and vigorous 
physical activity and poor validity for moderate activity 
and good reliability.52
Adherence to the Mediterranean diet
Adherence to the Mediterranean diet will be measured 
using the 14- item Mediterranean Diet Adherence 
Screener (MEDAS), developed within the prevention 
with Mediterrean diet (PREDIMED) study group.53 It 
includes items on food consumption and intake habits: 
the use of olive oil as the main source of cooking fat, pref-
erence for white meat over red meat, servings of vegeta-
bles, portions of fruit, red meat or sausages, servings of 
animal fat, sugar- sweetened beverages, red wine, legumes, 
fish, commercial pastries and dressing food with a tradi-
tional sauce made of tomatoes, garlic, onion or leeks 
sautéed in olive oil. The total score ranges from 0 to 14, 
with a higher score indicating a better accordance with 
the Mediterranean diet.54
Quality and patterns of sleep
Quality and patterns of sleep will be measured using the 
Pittsburgh Sleep Quality Index (PSQI).55 It differenti-
ates between ‘poor’ and ‘good’ sleep by measuring seven 
domains: subjective sleep quality, sleep latency, sleep 
duration, habitual sleep efficiency, sleep disturbances, 
use of sleep medication and daytime dysfunction over the 
past month. It consists of 19 self- applied questions and 
five questions that request the evaluation of the patient’s 
bedmate or roommate (these are not scored). Answers 
range from 0 (no difficulty) to 3 (severe difficulty). The 
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version, the Cronbach’s alpha coefficient is 0.81, sensi-
tivity is 88.63% and specificity is 74.99%. We will use the 
validated Spanish version.56
Personal factors on health behavior
We will assess: (1) self- efficacy57; (2) activation58; (3) 
sense of coherence59; (4) health literacy60 and (5) 
procrastination.61
Self-efficacy
Self- efficacy will be measured using the Self- Efficacy 
Scale.57 To measure General Self- Efficacy Subscale (17 
items including individuals' beliefs in their ability to 
perform well in a variety of situations) and Social Self- 
Efficacy Subscale (six items). It contains 23 items that are 
rated on a 14- point scale (ranging from strongly agree to 
strongly disagree). Higher scores indicate higher levels of 
self- efficacy. It has a Cronbach coefficient alpha of 0.86 
for General Self- Efficacy Subscale and 0.71 for the Social 
Self- Efficacy Subscale. The unpublished Spanish version 
was translated by Godoy in 1990.62
Patient activation in their own health
Patient activation in their own health will be measured 
using the Patient Activation Measure (PAM) Question-
naire with regard to the management of their health.58 
It evaluates the patient’s perceived knowledge, skills and 
confidence to engage in self- management activities. It has 
13 items with a Likert Scale from 1 (strongly disagree) 
to 4 (strongly agree). The resulting score (between 0 
and 100) places the individual at one of four levels of 
activation, each of which reveals insight into a range of 
health- related characteristics, including behaviours and 
outcomes. Higher scores indicate higher levels of activa-
tion.58 This scale is only validated in Spanish for chronic 
patients. It had an item separation index for the parame-
ters of 6.64 and a reliability of 0.98.63
Sense of coherence
Sense of coherence will be measured using the Sense of 
Coherence (SOC-13) Questionnaire by Antonovsky.59 It 
values the personal disposition towards the assessment 
of vital experiences. It measures the sense of coherence, 
comprehensibility, manageability and meaningfulness. 
It has 13 items scoring between 13 and 91 points. It has 
consistency rates between 0.84 and 0.93. Higher scores 
(after reversal of the inverted items) indicate a higher 
sense of coherence. We will use the validated Spanish 
version.64
Health literacy
Health literacy will be measured using the Health Literacy 
Europe Questionnaire (HLS- EUQ16).60 It can indicate 
that the probability of functional literacy in limited health 
is high, a possibility of functional literacy in limited 
health, and functional health literacy in adequate health. 
It contains 16 items. Higher scores indicate better health 
literacy. It presents a high consistency (Cronbach’s alpha 
of 0.982) in the Spanish validation.65
Procrastination
Procrastination will be measured using the Irrational 
Procrastination Scale (IPS).66 To measure general procras-
tination (dysfunctional delay). It has nine items, rated on 
a 5- point Likert Scale, with higher scores (after reversal of 
the three procrastination- inconsistent items) indicating 
a higher level of procrastination. Its Cronbach’s alpha 
value is 0.90. We will use the validated Spanish version.61
Data analysis plan
Analysis of the outcomes at baseline
First, descriptive analyses of all the variables (propor-
tions for qualitative variables, means and SD for quan-
titative variables) will be performed. Then, correlation 
analysis will be carried out between the questionnaires 
that evaluate personal factors on health behaviour (Self- 
Efficacy Scale, PAM, SOC-13, HLS- EUQ16 and IPS), 
social support (MOS- SS) and depression (BDI- II). We will 
also analyse the correlation between personal factors on 
health behaviour and the questionnaires assessing life-
style patterns (IPAQ- SF, MEDAS and PSQI). Finally, we 
will analyse the relation of lifestyle patterns and social 
support with depression. Inferential statistical analysis 
will be carried out using the χ2 test for qualitative vari-
ables, and Student’s t- test or one- wayanalysis of variance 
(ANOVA) test to assess the potential relationship between 
qualitative and quantitative variables.
Data collection and statistical analysis will be performed 
using Excel software, SPSS software (V.25.0)67 and the R 
statistical software environment (V.3.6.2).68
Clinical effectiveness analysis
The report of the results will follow a prespecified plan, 
based on the Consolidated Standards of Reporting Trials 
guidelines69 in order to compare the three groups using 
an intention- to- treat analysis and multiple imputation 
(MI) technique for handling missing data. Initially, a 
descriptive comparison (proportions, means or medians) 
will be carried out between groups for prognostic vari-
ables in order to establish their baseline comparability 
after randomisation. To analyse the clinical effectiveness, 
a repeated- measure linear regression will be conducted, 
including all evaluations over time. For this purpose, 
the main variable, BDI- II score, will be used as a contin-
uous variable. The models will include adjustments for 
the baseline value of the BDI- II and for any other vari-
able that would have shown differences in the baseline 
measurement. Possible group per time interactions will 
be examined using linear regression. Similar analyses will 
be carried out using the secondary outcomes (personal 
factors on health behaviour and assessment of lifestyle). 
To counteract the problem of multiple comparisons, we 
will use Bonferroni correction.
Comparisons will also be made between the LMP 
and LMP+ICTs groups regarding adherence to lifestyle 
modification requirements. Adherence will be consid-
ered as a good or beneficial score on the questionnaires 
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In addition, we will compare the LMP and combined 
LMP+ICTs groups, assuming that they are comparable to 
each other and the two groups have significant results.
A binary variable regarding comorbidity will be created 
(comorbidity yes/no). We will determine if the effec-
tiveness of the intervention differs in the subgroup 
presenting comorbidity and if the pathology improves. 
Statistical analyses will be selected based on subsample 
size (parametric or non- parametric tests).
As for the timepoint in which we administrate the 
follow- up questionnaires, we will consider the first 
follow- up assessment (in a period of 2–7 days after the last 
session of the intervention) as more relevant. We expect 
to find an immediate effect in the LMP and LMP+ICTs 
groups after attending group intervention, due to the 
potential social support received. In the 6- month and 
12- month follow- up, we expect a beneficial change in the 
questionnaires assessing lifestyle, reflecting a long- lasting 
effect.
Cost-effectiveness and cost-utility analysis
The effectiveness of the interventions will be estimated 
using the difference between the BDI- II baseline score 
and the score at the 6- month and 12- month follow- ups, 
and utility will be estimated using QALYs at the 6- month 
and 12- month follow- ups. QALYs will be calculated based 
on these scores using the Spanish EQ- 5D tariffs.70 Along 
with the EQ- 5D utility scores, scores recorded on the EQ 
VAS will also be used as an outcome for the analysis.
Cost- effectiveness will be explored through the calcu-
lation of incremental cost- effectiveness ratios (ICERs) 
for the active intervention groups (LMP and LMP+ICTs) 
using the TAU group as the control. ICER is defined as 
the ratio between incremental costs and incremental 
effectiveness. In this way, cost utility will be explored 
by calculating incremental cost- utility ratios, which are 
defined as the ratio between incremental costs and incre-
mental utilities measured on QALYs. QALYs gained in 
each evaluation are approximated using the area under 
the curve technique.71
Total costs will be calculated by adding direct and indi-
rect costs. Direct costs will be calculated by adding the 
costs derived from the medication and the use of health 
services and clinical tests. The medication costs will be 
calculated by determining the price per milligram during 
the study period according to the vade- mecum of the last 
year of study, including value- added tax. The total cost of 
drug treatment will be calculated by multiplying the price 
per milligram by the daily dose in milligrams and the 
number of days the treatment is received. Costs derived 
from the use of health services will be calculated consid-
ering the data from the Oblikue database.72 Indirect costs 
will be calculated based on the sick leave days and multi-
plying them by the Spanish minimum daily wage during 
the study period, 2019–2020.
We assume that data will be missing at random. Only 
patients with both cost and relevant outcome data at the 
6- month and 12- month follow- ups will be included in the 
cost- effectiveness and cost- utility analyses. Notwithstanding 
this, sensitivity analysis imputing missing 6- month and 
12- month data will test the robustness of cost- effectiveness 
and cost- utility results. The imputations will be performed 
using the ‘mice’ package,73 freely available in the Compre-
hensive R Archive Network (CRAN- R).68
DISCUSSION
Depression is a significant cause of morbidity having low 
detection and treatment rates in primary care.74 75 Only 9% 
of all depressed primary care patients receive adequate treat-
ment, and only 6% achieve remission, making depression an 
important management issue in primary care.76 An effective 
treatment for depression that can be implemented in PHCs 
is brief psychotherapy (six to eight sessions programmes), 
which have the advantage of being performed by either 
mental health professionals or trained non- mental health 
providers.77 In this case, the promotion of healthy lifestyles 
will be used to address depressive symptoms, as it has shown 
efficacy in a number of studies.20–31 To ensure treatment 
adherence, facilitators should be used, such as the use of ICTs 
and the group format. They provide monitoring and social 
support, respectively.33 Organising group therapies in PHCs 
generates a range of organisational benefits, in relation to 
efficient use of facilities, high therapist- to- patient ratios and 
potential reductions to treatment wait times.78 Moreover, 
participants are just as likely to engage in group treatment 
as individual work and the benefits are also maintained over 
time.79
The strengths of this study include the design and the 
wide range of outcome measures. It will provide a wealth of 
information on the interplay between depression, personal 
factors on health behaviour and lifestyles. Study limitations 
include the possible attrition of participants due to session 
scheduling or participant refusal to participate in a group 
intervention or do the complete follow- ups.80 However, the 
possible reasons for attrition and other issues will be regis-
tered regarding MAGI framework.38
Therefore, the creation of a six- session group programme 
addressing lifestyle modifications (plus testing the moni-
toring with ICTs by adding a smartwatch to one of the inter-
vention group) appears to be a good choice for depression 
treatment. The long- term aim of this study is to establish 
intervention for patients with depression, making it acces-
sible in their PHCs, effective and cost- effective.
Execution dates
Initial recruitment of patients: April 2020.
Finalisation of patient recruitment: May 2020.
Finalisation of patient monitoring period: June 2021.
Publication of results: July 2021.
Partial patient and public involvement (PPI)
PPI representatives worked with us to refine the research 
question; however, it was difficult to involve patients in other 
areas of the study design due to data protection restrictions 
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analysis. PPI representatives will write a plain language 
summary and design a leaflet for dissemination to their peers 
and distributing to patient groups.
ETHICS APPROVAL
Ethics approval was granted by the Clinical Research Ethics 
Committee of Aragón (PI18/286) and the Research Ethics 
Committee of the Balearic Islands (IB3950/19 PI). The study 
has been developed in accordance with the Declaration of 
Helsinki. All of the subjects will sign an informed consent 
form, their data will be anonymised and will only be used 
for the purposes of the study. Participants and healthcare 
professionals will be informed about the results. Patients of 
the TAU group will be invited to participate in the LMP at the 
end of the study. The ethics committee will be notified of any 
protocol modifications.
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